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Abstract
Background—Nephronophthisis-associated ciliopathies (NPHP-AC) comprise a group of
autosomal recessive cystic kidney diseases that includes nephronophthisis (NPHP), Senior-Loken
syndrome (SLS), Joubert syndrome (JBTS), and Meckel-Gruber syndrome (MKS). To date,
causative mutations in NPHP-AC have been described for 18 different genes, rendering mutation
analysis tedious and expensive. To overcome the broad genetic locus heterogeneity we devised a
strategy of DNA pooling with consecutive massively parallel resequencing (MPR).
Methods—In 120 patients with severe NPHP-AC phenotypes we prepared 5 pools of genomic
DNA with 24 patients each which were used as templates in order to PCR-amplify all 376 exons
of 18 NPHP-AC genes (NPHP1, INVS, NPHP3, NPHP4, IQCB1, CEP290, GLIS2, RPGRIP1L,
NEK8, TMEM67, INPP5E, TMEM216, AHI1, ARL13B, CC2D2A, TTC21B, MKS1, and
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XPNPEP3). PCR products were then subjected to MPR on a Illumina Genome-Analyzer and
mutations were subsequently assigned to their respective mutation carrier via CEL I endonuclease-
based heteroduplex screening and confirmed by Sanger sequencing.
Results—For proof of principle we used DNA from patients with known mutations and
demonstrated the detection of 22 out of 24 different alleles (92% sensitivity). MPR led to the
molecular diagnosis in 30/120 patients (25%) and we identified 54 pathogenic mutations (27
novel) in 7 different NPHP-AC genes. Additionally, in 24 patients we only found single
heterozygous variants of unknown significance.
Conclusions—The combined approach of DNA pooling followed by MPR strongly facilitates
mutation analysis in broadly heterogeneous single-gene disorders. The lack of mutations in 75%
of patients in our cohort indicates further extensive heterogeneity in NPHP-AC.
Keywords
Next-generation sequencing; Ciliopathy; Nephronophthisis
INTRODUCTION
Dysfunction of the primary cilium / basal body complex has been implicated in the
pathogenesis of NPHP-associated ciliopathies (NPHP-AC) including nephronophthisis
(NPHP), Senior Loken syndrome (SLSN), Joubert syndrome (JBTS), and Meckel-Gruber
syndrome (MKS).[1] NPHP-AC are rare, genetically heterogeneous, autosomal recessive
inherited disorders, which share a broad phenotypic spectrum as a result of ciliary/
centrosomal defects in various cell types, e.g. retinal photoreceptors or renal tubular
epithelial cells.[2] In NPHP, kidney tubular basement membrane disintegration, tubular
atrophy, interstitial fibrosis, and cyst formation results in progressive renal failure during
childhood or adolescence. About 15% of patients develop extrarenal manifestations, in
particular, progressive retinal dystrophy, referred to as SLSN. In patients with JBTS,
midbrain-hindbrain malformations and cerebellar vermis hypoplasia /aplasia results in
numerous neurological features including developmental delay, intellectual disability,
muscle hypotonia, ataxia, oculomotor apraxia, nystagmus, and irregular breathing patterns in
neonates.[3] The most severe manifestation of the NPHP-AC clinical spectrum is seen in
fetuses with Meckel-Gruber syndrome, a perinatally lethal ciliopathy, characterized by
central nervous system malformations (typically occipital encephalocele), bilateral postaxial
hexadactyly, hepatobiliary ductal plate malformation, and multicystic dysplastic kidneys.
Mutations in 18 different recessive genes have been identified as the molecular cause in
NPHP-AC (Table 1). Twelve genes have been implicated in NPHP and/or SLSN (NPHP1,
INVS, NPHP3, NPHP4, IQCB1, CEP290, GLIS2, RPGRIP1L, NEK8, TMEM67, TTC21B,
and XPNPEP3).[4–15] Ten are known to cause Joubert syndrome (AHI1, TMEM216,
INPP5E, NPHP1, CEP290, RPGRIP1L, TMEM67, ARL13B, CC2D2A, TTC21B).[16–25]
Mutations in 5 genes (MKS1, TMEM67, CEP290, RPGRIP1L, CC2D2A, TMEM216) have
been shown to cause MKS [12, 17, 26–29]. Multiple allelism within the NPHP-AC
phenotypic spectrum has been recurrently reported for many of these genes, especially
CEP290, RPGRIP1L, TMEM67, CC2D2A, TTC21B, and TMEM216. For example,
hypomorphic missense mutations in the gene TMEM67 (MKS3/NPHP11) are implicated in
NPHP with liver fibrosis and JBTS type 6, whereas truncating mutations in TMEM67/MKS3
have been reported in MKS cases with severe developmental and dysplastic phenotypes.[14,
22, 27] The presence of multiple allelism and broad heterogeneity together with extensive
phenotypic clinical overlap in patients with NPHP-AC requires extensive mutational
analysis efforts in order to identify the underlying molecular etiology. The challenge of
analyzing increasing numbers of candidate genes associated with disease in large cohorts of
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patients can now be met by applying next-generation sequencing technologies. We chose to
perform single PCR reactions with well established primer pairs, rather than trying
implementing multiplexing, in order to amplify all coding exons (376) of 18 known NPHP-
AC disease genes. In order to reduce the calculated number of 45,120 PCR reactions,
required to amplify all 376 exons in 120 individuals, we devised a pooling strategy by
generating 5 DNA pools derived from 24 individuals each. Identification of the mutation
carrying individuals was done by CEL1 endonuclease-based heteroduplex analysis and
Sanger sequencing.[30] We demonstrate that the approach of pooling DNA samples in
combination with MPR is a robust, economic, and highly effective method for examining
larger patient cohorts for mutations, especially in diseases with broad genetic locus
heterogeneity.
An overview of the various steps undertaken, including DNA pooling, PCR, MPR, and
mutation carrier identification is depicted in a flowchart (Figure 1).
MATERIALS AND METHODS
Human subjects
We obtained blood samples, pedigrees, and clinical information after receiving informed
consent (www.renalgenes.org) from all patients. Approval for experiments on humans was
obtained from the University of Michigan Institutional Review Board. The cohort of 120
patients with severe NPHP-AC included 54 (45%) patients diagnosed as JBTS with kidney
involvement, 14 (12%) patients with SLSN, 6 (5%) patients with MKS, and 46 (38%)
patients with NPHP and early onset of end-stage renal disease before age 7 years. The
cohort consisted of 56 (47%) familial cases vs. 64 (53%) sporadic cases. Consanguinity was
known to be present in 30 (25%) families. As a first diagnostic step, homozygous deletions
of NPHP1 were excluded in all patients by multiplex PCR.[30] Total genome homozygosity
mapping was performed in 114 of 120 patients. In patients exhibiting long runs of
homozygosity (most likely by descent) at known NPHP-AC loci, exon sequencing for
respective genes was carried out and was negative. Ninety-six healthy control DNA samples
(Human Random Control DNA panel-1, HRC-1) were obtained from the European
Collection of Cell Cultures (ECACC, Salisbury, United Kingdom).
Whole genome amplification and DNA pooling
In order to normalize various DNA samples of dissimilar quality, whole genome
amplification (WGA) was performed by individually amplifying 10 ng genomic DNA of
120 different individuals and 96 healthy control samples. Using Phi29 based DNA
polymerase strand displacement amplification according to the manufacturer’s instructions
(GenomiPhi DNA amplification kit, GE Healthcare). Subsequently, DNA was purified using
96 well spin columns (Rapid 96TM PCR purification system, Marligen-Biosciences).
Genomic DNA of 24 individuals was pooled at 2 µg each and diluted to 60 ng/µl. Five pools
were generated to represent 120 individuals. As a control, another equimolar DNA pool was
generated, by pooling 96 DNA samples derived from healthy individuals of Caucasian
origin [Human Random Control DNA Panel-1 (HRC-1)].
PCR amplification
All 376 exons of the genes NPHP1 (20 exons), INVS (16), NPHP3 (28), NPHP4 (30),
IQCB1 (15), CEP290 (54), GLIS2 (6), RPGRIP1L (27), NEK8 (15), TMEM67 (28), INPP5E
(10), TMEM216 (5), AHI1 (27), ARL13B (10), CC2D2A (37), TTC21B (29), MKS1 (18), and
XPNPEP3 (10) were individually amplified using pairs of exon flanking primers
(Supplementary Table 1) in each of the DNA pools as the PCR-template. A 12 µl total
volume single PCR reaction was set up with 120 ng (2 µl) of pooled DNA derived from 24
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different patients (5 ng of each DNA), 2.5 pmol of each forward and reverse primer, and 6 µl
HotStar-Taq Polymerase mixture (Qiagen). DNA amplification was performed on a thermal
cycler (Mastercycler, Eppendorf) using Thermo-Fast® 96-well plates (ABgene), applying
the following touchdown PCR protocol for all PCR reactions: Initial denaturation at 94°C
for 15 min, followed by 24 cycles with an annealing temperature decreasing 0.7°C per cycle,
starting at 72°C for 30 sec; denaturation at 94°C for 30 sec, and extension at 72°C for 1 min.
An additional 20 cycles with fixed annealing temperature were added: 94°C for 30 sec, 55°C
for 30 sec, 72°C for 1 min with a final extension of 72°C for 10 min. Two µl of each
reaction was analyzed by agarose gel-electrophoresis (1.2% agarose, 120V, 1 hour).
Enzymatic modification of PCR products prior to MPR
For each pool, we combined 5 µl of each of the 376 exonic PCR products ranging from 139
bp to 1,236 bp and purified the DNA fragments on 3 separate columns of a QIAquick PCR
Purification Kit (Qiagen). In order to generate random start positions for next-generation
sequencing, to reduce the presence of primer sequences and adjacent intronic sequences, and
to reduce fragment sizes, we digested the mixture of PCR products with BAL-31
exonuclease and DNase I endonuclease. Ten µg of the purified PCR fragment mixture was
digested with 5 units of BAL-31 exonuclease (New England Biolabs) for 5 min at 30°C in a
200 µl reaction. The reaction was stopped by adding EGTA to a final concentration of 20
mM and immediately heat inactivated at 65°C for 10 min, followed by Qiaquick PCR
column purification (Qiagen). Remaining DNA (about 2 µg) was further digested by
incubating with 1 unit DNAse I (Roche) and freshly prepared reaction buffer [2x reaction
buffer contains 20 mM Tris-Cl (pH 7.5), 2 mM CaCl2, and 20 mM MnCl2] for 3 min at
16°C. In the presence of Mn2+ ions, the DNase I enzyme cleaves both DNA strands at
approximately the same site. [31] The reaction was stopped by adding 2 µl EDTA (500 mM)
and immediately heat inactivated at 65°C for 10 min. Afterwards, DNA was purified using
Qiaquick columns (Qiagen) and eluted with 30 µl EB buffer.
Next-generation sequencing on a Solexa/Illumina GA2 platform
Library construction of the modified PCR fragment mixture was performed using “Genomic
DNA Sample Prep Kit” according to the manufacturer’s instructions (Illumina, San Diego,
CA). Fragments were separated on a 1.5% agarose gel and excised in the 150–200 bp range.
Fragments were then purified and subjected to 10 rounds of PCR amplification using
complementary linker specific primers. The amount and size distribution of each sample was
analyzed on a Bioanalyzer 2100 (Agilent Technologies, Inc). For next-generation
sequencing, single-stranded DNA fragments were annealed to a flow cell surface in a cluster
station (Illumina) and subjected to 46 cycles of bridge amplification. Fragments were run on
a single lane of a Solexa/Illumina Genome Analyzer II platform, generating about 15–20
million single-end sequence reads of 39 bases each. Image analysis and base calling was
generated by the Genome Analyzer Pipeline 1.5.1 with default parameters. Illumina specific
FASTQ files containing sequence information and quality scores for each base call were
exported for downstream analyses.
Sequence read mapping and variant calling
Sequence alignment was performed with ‘CLC Genomics Workbench™’ software (CLC-
bio, Aarhus, Denmark) using imported and annotated human reference genome assembly
hg18 (NCBI build 36) chromosome sequence files as a reference. We annotated all 24
human chromosomal reference data sets with gene transfer files (GTF) after downloading
dbSNP(v130) from UCSC and by annotating all obligatory splice sites. After importing the
concatenated FASTQ (Illumina) files generated by the GAII pipeline into the CLC-software,
sequence reads were mapped to exonic coding regions plus adjacent 100 bp intronic
sequence of all 376 initially PCR-amplified targets. Gapped alignments with default
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parameters applying bioinformatic costs for mismatches of “2” and indel costs of “3” was
performed. Variant calls were obtained using the following filter parameters: Coverage ≥
300X, variant frequency of at least 0.7%, and a minimum variant count of 5 reads. The
variant analysis included coordinates of obligatory splice sites, and all variants predicted to
change the amino acid sequence (missense, nonsense, and coding indels). When calling
variants from normal reference sequence (VRS), we excluded all synonymous variants and
all variants localized in non-coding exonic regions or in introns (except obligatory splice
sites). Furthermore, we excluded known SNPs (v130) and all variants identified in the
healthy control pool MPR experiment processed in parallel using identical filter parameters
(coverage, minor allele frequency, and minimal counts). To prioritize for downstream
analysis we scored missense variants according to the information of evolutionary
conservation and the likelihood of a potential protein damaging effect using PolyPhen2
software predictions (http://genetics.bwh.harvard.edu/pph/).[32] All variants with a
predicted “probable” or “possible” damaging effect and a score above 0.7 (PolyPhen2) were
further analyzed in the original unpooled DNA samples of 24 pooled individuals by CEL1
heteroduplex analysis and/or direct Sanger sequencing.
Identifying mutation carriers out of 24 pooled individuals
In order to identify the carrier(s) of the selected VRS (114 altogether) from a pool of 24
patients, standard mutation detection techniques were applied. The mutation containing exon
was amplified by PCR using genomic DNA of all 24 patients as template in separate
reactions. Subsequently, the PCR products were analyzed using CEL I heteroduplex
screening or using direct Sanger sequencing.[30] In all cases in which only one mutated
allele was discovered, we screened for a potential second mutated allele by Sanger
sequencing all exons of the respective gene.
RESULTS
Proof of principle for pooled DNA sample analysis
In a pilot project we tested the DNA pooling and next-generation sequencing strategy by
pooling the DNA of 18 patients (36 alleles) with known mutations in 18 different NPHP-AC
causing genes (Table 1, Supplementary Table 2). The equimolar DNA pool contained
altogether 14 different heterozygous and 10 different homozygous mutations/variants. From
a total of 24 different mutations/variants, 9 were missense, 8 were nonsense, 2 were small
insertion/deletions, 2 were synonymous rare polymorphisms, and 3 were affecting
obligatory splice sites. After MPR of 376 different pooled PCR products derived from the
DNA pool of 18 different mutation carriers, the analysis revealed confirmation of 22 out of
24 known mutations/variants (92%) (Supplementary Table 2). For the two mutations
(p.S360T in NPHP3, and R85X in TMEM216) that were not detected, there was a lack of
coverage of the respective exons with only two or zero variant sequence reads, respectively
(Supplementary Table 2). Mutations were detected after filtering for variants affecting
amino acid residues, reading frames, or obligatory splice sites by setting parameters for
variant calls for minor allele frequency to ≥ 0.7%, minimum coverage to ≥ 300×, and the
minimum number of reads (counts) to ≥ 5 as described in methods.
Statistics on Solexa/Illumina GA2 sequence runs of pooled DNA samples
Next-generation sequencing of 376 different PCR products generated by using pooled DNA
samples was carried out on a Illumina/Solexa GA2 platform (one pool per lane of a flow
cell). In addition to 5 experimental patient’s DNA pools (Patient-pool 1>5) generated by
pooling 24 samples each, we sequenced the PCR products derived from a pool of 96 healthy
control individuals (HRC1-individuals) and one positive control pool derived from 18
patients with known mutations. Statistical features of Solexa/Illumina sequence runs
Otto et al. Page 5
J Med Genet. Author manuscript; available in PMC 2014 February 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
representing the 5 experimental patient pools are shown in Table 2. One lane of a 8-lane
flow cell GA2 run delivered on average about 16.7 million (range: 15.5 M to 19.9 M) short
reads of 39 bases. After gapped alignment to the human reference sequence, 85% of all
reads mapped back to one of the 376 targeted amplicons (18 genes). The sequence
concatenation of all 376 amplicons amounts to a total length of 147.5 kb, 52.8 kb of which
were exonic coding regions. The median coverage for coding nucleotide sites was 4,186X
(mean: 5,753X), which translates into a median depth of 87X (mean: 120X) per site per
single allele, respectively. An example of the overall coverage of all concatenated exons
derived from 18 NPHP-AC genes is shown in Figure 3 for patient pool #3. The overall
maximum coverage of 54,386X was found in patient pool #5. On average, about 95% of the
targeted coding regions were sufficiently covered at least 300-fold in order to reliably call a
heterozygous mutation/variant present on only one out of 48 pooled alleles derived from 24
patients.
Mutation carrier identification by CEL I endonuclease heteroduplex screening and Sanger
sequencing
MPR of PCR products of 120 individuals revealed initially a total of 379 variants within
coding regions of 18 genes analyzed, 119 of which were known SNPs (Table 2). Performing
MPR on a healthy control sample pool in parallel reduced the remaining 260 variants by
another 49 variants (Table 2). These variants were either unknown SNPs identified in the
human random control pool or false calls due to software base calling or alignment artifacts.
Of the remaining 211 variants, 114 truncating mutations (nonsense, frameshift), canonical
splice sites and missense changes with a predicted “damaging” impact at the protein level
(PolyPhen2 score >0.7) were followed up by identification of the contributing individual.
CEL I heteroduplex screening and direct Sanger sequencing were subsequently performed
for the 114 variants in order to identify the mutation carrier(s) out of the respective pool of
24 patients. This carrier analysis led to the confirmation of 75 (65%) mutations/variants
(“true positives”), whereas 40 variants could not be confirmed (“false positives”) (Table 2).
The distribution of` “false” versus “true positive” were plotted in respect to the variant allele
frequency (x-axis) and the absolute sequence reads (counts) present for each of the 114
variants analyzed (Figure 4). The likelihood for a variant allele to be “true positives” was
found to increase as expected, with higher absolute allele counts and/or higher relative
variant allele frequency. In order not to miss mutations we choose relaxed SNP call
parameters of 0.7% for the variant allele frequency with at least 5 absolute counts (reads).
This has especially increased “false positive” variants with allele frequencies between 0.7%
and 1% (Figure 4). CEL I heteroduplex analysis helped to identify 44 out of altogether 74
variants during the initial screen, but failed in 14 cases to identify the change, as
subsequently revealed by Sanger sequencing (in Table 4, 5 indicated as “CEL I negative”).
All other variants/mutations have been identified solely by Sanger sequencing without CEL
I prescreening. For patients in whom initially only one mutation has been identified, we
searched for a second mutated allele by direct Sanger sequencing all exons of the respective
gene. This approach led to the identification of 10 additional mutations.
Detection of disease causing mutations in 30 out of 120 patients
MPR mutation analysis of all coding exons of 18 different NPHP-AC genes (Table 1) in 120
ascertained patients with a severe recessive NPHP-AC disease led to the identification of 57
mutated alleles, comprising 43 different mutations in 30 unrelated patients (Table 3).
Twenty four patients carried a compound heterozygous mutation. In 3 patients with a
consanguineous background, a homozygous disease allele was identified in CEP290
(p.L972P and p.G1890X twice) (Table 3). In 3 patients, only 1 mutated allele (IQCB1,
p.R364X; CEP290, p.K484fsX8; and AHI1, p.R891X) has been identified so far, even
though all exons of the respective mutated gene have been sequenced directly. Mutations
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were discovered in the genes NPHP4 (2 patients), IQCB1/NPHP5 (1 patient), CEP290/
NPHP6 (9 patients), RPGRIP1L/NPHP8 (1 patient), TMEM67/NPHP11 (10 patients), AHI1
(1 patient), CC2D2A (3 patients), and TTC21B (3 patients) (Table 3). The category of
mutated alleles identified in the present study are as following: 14 nonsense mutations, 11
small insertion/deletions leading to a frameshift, 1 inframe deletion, 3 splice site mutations,
and 25 missense mutations (Table 3). Twenty seven of these mutations were novel findings
in the genes NPHP4 (p.N102fsX76, p.W1023X, p.T1122P, p.R1135fsX10), IQCB1
(p.R364X), CEP290 (p.E46X, p.G397S, p.K484fsX8, p.L972P, p.E1728X, p.E1771X,
p.L1815fsX4), RPGRIP1L (p.N241fsX25, p.H610P), TMEM67 (p.K329T, p.R463X,
p.F637L, p.V673A, p.Y723C, p.T964I, c.2556+1G>A splice), AHI1 (p.R891X), and
CC2D2A (p.E229del, p.L559P, p.W1182R, p.E1259fsX1, p.V1298D) (Table 3, Figure 2).
All mutations were absent from 96 healthy control individuals. In all cases where DNA of
relatives was available, recessive mutations segregated with the affected status and
segregated from parents as expected. In 17 out of 30 families segregation analysis has been
performed and paternal (p) or maternal (m) inheritance has been indicated for respective
mutations accordingly in Table 3. The heterozygous TMEM67 mutation p.C615R was found
recurrently in 5 different families of German origin. Comparison of SNP genotype linkage
data, generated by 250k (StyI) Affymetrix SNP analysis, is compatible with extensive
haplotype sharing between respective patients and extends up to 4.2 Mb (204 SNP markers),
indicating inheritance from an ancestral founder (data not shown).
Single heterozygous variants of unknown significance
Mutation analysis by MPR of 18 known disease genes revealed additional 26 single
heterozygous missense mutations/variants of unknown significance in 24 patients out of the
120 patients analyzed (Table 4). All changes were absent from at least 96 healthy control
individuals. For all 26 missense changes Sanger sequencing was performed for all exons of
the respective disease gene, but failed to detect a second mutated allele. Patients of families
A75 and A1421 carried heterozygous missense mutations/variants in different disease genes.
In a patient from Poland (A75) with nephronophthisis, a heterozygous p.N85T mutation/
variant in CEP290 together with a p.Y655C change in the gene RPGRIP1L was detected.
The positions of both missense changes were evolutionary conserved in vertebrates
including zebrafish. PolyPhen2 software predicted a probable protein damaging effect for
both missense changes (Table 4). Individual A1421 from Egypt with Joubert syndrome and
liver fibrosis carries the heterozygous missense changes in TMEM67 (p.G821S) and
CC2D2A (p.R1019G). Interestingly, the mutation p.G821S has been found homozygously in
patients with nephronophthisis with liver fibrosis, published recently (Otto et al., 2009). The
amino acids of both missense changes found in family A1421 are highly conserved in
evolution including the nematode Caenorhabditis elegans. Altogether, we identified 21
different single heterozygous mutations/variants in the genes NPHP3 (1), NPHP4 (2),
IQCB1 (1), CEP290 (1), RPGRIP1L (2), TMEM67 (5), ARL13B (1), CC2D2A (3), TTC21B
(3), MKS1 (1), and XPNPEP3 (1). The mutation p.G821S in TMEM67 and heterozygous
changes p.K507E and p.P721S in the gene CC2D2A have been found recurrently (Table 4).
Five out of the 21 different single heterozygous changes have been published previously as
disease causing in a recessive setting and are documented in the Human Gene Mutation
Database at the Institute of Medical Genetics in Cardiff (HGMD®, “Biobase” (http://
www.biobase-international.com/) (Table 4).
DISCUSSION
Applying next-generation sequencing technology helped us to identify the disease causing
mutations in 30 out of 120 patients with severe NPHP-AC. Altogether, we identified 43
different mutations, 28 of which were novel findings within 9 different NPHP-AC genes.
Otto et al. Page 7
J Med Genet. Author manuscript; available in PMC 2014 February 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Additionally, we found single heterozygous missense changes of unknown significance in
25 patients in 11 out of 18 genes analyzed. We demonstrated that high throughput
sequencing using pooled DNA samples is highly efficient in detecting rare mutations in
large cohorts of patients with diseases of broad genetic locus heterogeneity. Applying MPR,
we screened 376 coding exons derived from 18 different NPHP-AC genes in 120 patients,
which comprises more than 45,000 different amplified DNA fragments. Alternative
methods, to screen such a large amount of single PCR products, like standard Sanger
sequencing, although accurate and reliable, is prohibitively expensive ($180,000) and would
require 45,000 single PCR amplifications. CEL1 heteroduplex screening alone without high-
throughput sequencing on the other hand is less expensive (estimated costs $12,000),
however it would require laborious and time consuming analyses of about 450 different 96-
well plates. Another alternative approach is exon capture in combination with next-
generation sequencing, which might be considered when a large number of exons (or the
total exome) have to be analyzed for a reasonable number of DNA samples (about $4,000/
exome/sample). In comparison, the cost of generating sequence data by MPR of 5 pooled
samples (376 exons, 120 patients) and subsequent confirmation analyses in the present study
was in the range of $6,000. The disadvantage of MPR is the high inherent error rate of about
0.5% per base call. This is problematic especially when samples are pooled and the expected
variant frequencies are very low, which certainly will result in high false positive rates. Out
of 114 mutations/variants which were predicted after alignment and next-generation
sequencing software analysis, only 74 (65%) have been confirmed by Sanger sequencing.
Recently, we applied the pooling and MPR strategy also to a cohort of 105 patients with
Bardet-Biedl syndrome and screened for mutations in 12 BBS genes. Soft- and hardware
improvements of the Illumina sequencers are constantly increasing the number and quality
of sequence reads. Interestingly, 100% of the exonic bases in all BBS genes were covered
sufficiently (> 300×) with an average coverage of 19,711 after analyzing the most recent
sequence run with 28 million short reads. After alignment 11 out of 12 (92%) of the
predicted mutations have been directly confirmed by Sanger sequencing (manuscript in
preparation). The increased number of sequence reads and the resulting increased base
coverage seems to reduce false positive calls dramatically. Better coverage can be also
obtained by generating longer (e.g.78 bases) and/or paired-end sequence reads. This will
further reduce calling false positives and will strongly reduce the number of confirmation
experiments using CEL I endonuclease digestion.
In order to reliably detect a heterozygous variant/mutations in a pool of 48 alleles (expected
frequency: 2.1%) after generating a total of up to 800 Mb worth of sequence, we choose
cutoffs for minor allele frequency of 0.7% and a minimum count of 5 reads. In a pilot
project with 18 pooled DNA samples from patients with already known mutations we were
able to identify all but 2 out of 24 known mutated alleles using the outlined cutoff
parameters. In both of these missed alleles, the coverage depth was insufficient due to PCR
amplification problems.
The question arises, how many mutations might have been missed in the experimental
pooling and MPR approach in the 120 patients investigated. We have recognized insufficient
coverage below 300× for about 5% of all coding nucleotides out of a total of the 52.8 kb
sequenced and expect therefore at least 5% of mutations to be missed. MPR of PCR
amplicons generated from pooled DNA samples revealed initially 114 potential mutations
using CLC genomics workbench software for alignment and analysis. Seventyfour (65%) of
these variants have been finally confirmed by Sanger sequencing, 41 of which represented
single heterozygous changes only, without a second mutated allele identified initially.
However, Sanger sequencing of all exons of the respective gene in carriers of these single
heterozygous changes revealed the second recessive mutation in 10 patients. This indicates
that we have missed at least 12% (10/87) of mutations/variants during the initial analysis.
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The calculated likelihood to miss both mutations of a patient with a compound heterozygous
mutation is only in the range of 1–2% (0.12×0.12). Besides the mutations we missed
because of low coverage depth, there were 3 different 4 bp deletions with sufficient
coverage which were missed using the CLC next-generation sequence software. To address
the problem of detection of small indels (4 and more bases) in short reads (39 bp) the use of
other software packages have to be considered like “NextGENe®” from the company
Softgenetics or the program “Novoalign” from Novocraft. For longer reads of e.g.78 bp, we
found that CLC next-generation sequence software reliably calls indels of up to 6 bases. To
date, the mutation rate of indels (4 or more bases) in NPHP related genes published in the
HGMD® ‘Biobase’ mutation database (release 25th June 2010) is about 6%. Out of 457
different mutations published in the 18 NPHP related genes, 28 (6.1%) fall into this category
of 4 or more bases inserted or deleted.
MPR revealed 24 patients with only 1 heterozygous missense change in one gene or 2
missense changes in 2 different genes (3 families, Table 4). We speculate that in most of
these cases a second mutated allele has been missed, although all exons have been analyzed
by Sanger sequencing. Examples could be, gross rearrangements, copy number variations,
deep intronic splice affecting changes, promotor mutations, or polyadenylation signal
variants, which were not detectable by solely coding exon sequencing. Some of the changes
found, might represent only rare polymorphism without any disease relevance. We have not
found any evidence that oligogenicity is involved in NPHP-AC, although we sequenced 120
patients for all known relevant 18 NPHP-AC genes.
The approach of MPR of pooled samples presented here is robust, cost efficient, and best
suited for screening large cohorts for mutations in genetically heterogeneous diseases. The
lack of sensitivity seen so far for the MPR of pooled sample approach makes a clinical
diagnostic application impracticable. In cases where numerous changes are expected or in a
clinical mutation diagnostic setting, “barcoding tags” offer an alternative and should be
considered. However, that approach requires additional library preparations, large amounts
of single PCR reactions or establishment of very complex multiplex PCRs reactions.[43]
Anticipated future sequencing technology improvements will allow parallel mutation
analysis of higher numbers of genes and DNA samples. This is especially of interest because
the lack of mutations in 75% of patients in our cohort indicates further extensive
heterogeneity in NPHP-AC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Flowchart illustrating the various steps of the DNA pooling and massive parallel
resequencing approach, which was applied in order to perform mutation analysis for 18
genes in 120 patients with nephronophthisis associated ciliopathies.
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Figure 2.
Sequence chromatograms of 28 different novel mutations identified in the genes NPHP4 (4),
IQCB1 (1), CEP290 (8), RPGRIP1L (2), TMEM67 (7), AHI1 (1), and CC2D2A (5) in
individuals with a NPHP-AC. Gene name, patient identifier, nucleotide change, and inferred
amino acid alteration are given above sequence traces. Wild type sequence chromatograms
are shown below mutated sequences. All mutations were absent from at least 96 healthy
control individuals. Note, that no second mutation has been identified in patients A394,
A2420, and F787 in whom we identified a heterozygous truncating mutation in the genes
IQCB1 (p.R364X), CEP290 (p.K484fsX8), and AHI1 (p.R891X), respectively. All
mutations were found in the heterozygous state with the exception of a homozygous
CEP290 missense mutation (p.L972P) in patient F335.
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Figure 3.
Obtained coverage depth along the entire concatenated sequence of all 376 amplicons (145
kb) derived from 18 different NPHP-AC genes. Shown as an example are the results from
the MPR mutation analysis performed on 1 lane of a Solexa/Illumina flowcell in patient pool
#3 (DNA pool of 24 patients). Note that exonic but also partial intronic regions of all
amplicons are shown. The median coverage depth within exonic coding regions (total of 54
kb) is 4,186×. About 95% of all coding bases are covered at least 300-fold.
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Figure 4.
Sanger sequencing confirmation of “true mutations/variants” (filled diamonds) identified by
MPR on Solexa/Illumina platform are plotted versus variants not confirmed “false positive”
(open circles). The alignment of a total of about 83 million sequence reads (39 bp each) to
the human reference sequence of targeted 376 exons using “CLC Genomics Workbench™”
software revealed 114 variants/mutations fulfilling the following criteria: i) absent from SNP
database SNPv130, ii) absent from a control pool of 96 DNAs of healthy individuals, and iii)
damaging impact at protein level predicted by PolyPhen2 with scores above 0.7. The variant
frequency (x-axis) is plotted against the variant counts (y-axis) for each of the 114 variants
analyzed. Seventy four variants/mutations have been confirmed by Sanger sequencing (filled
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diamonds) and we identified the respective mutation carrier out of a pool of 24 patients.
Note that Sanger sequencing confirmation (filled diamonds) has been successful for only 3
variants with allele frequencies below 1%. The expected frequency of a heterozygous
change found in a pool of 24 patients DNA is about 2.1%. Changes with frequencies above
1% and high absolute counts (>50) are almost always confirmed by Sanger sequencing.
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